Breaking Down Betta Pharmaceuticals Co., Ltd. Financial Health: Key Insights for Investors

Investors scrutinizing Betta Pharmaceuticals Co., Ltd. (300558.SZ) will want to weigh a mix of robust top-line growth and mounting liquidity pressures: third-quarter 2025 revenue came in at 985.93 million CNY (+16.83% YoY) and trailing twelve-month revenue reached 3.26 billion CNY (+18.40% YoY) against a market capitalization of about 19.90 billion CNY, yet profitability and cash dynamics tell a more cautious story-first-half 2025 net profit dropped to 140 million CNY (-37.53% YoY), quarterly free cash flow was a negative -263.26 million CNY, and cash on hand stood at 491.93 million CNY as of September 2025 (-39.74% YoY); add a TTM P/E of 59.77, EV/FCF of 460.22 and a current ratio of 0.77 to the mix, alongside a manageable debt-to-equity of 0.42, and you get a company with significant R&D-driven upside-including a 3rd-gen EGFR-TKI and long-acting ophthalmic candidates-and analyst forecasts of 42.2% annual EPS growth and 19.2% annual revenue growth over the next three years, making the trade-off between near-term liquidity risk and potential long-term value a compelling reason to read on.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Revenue Analysis

Betta Pharmaceuticals' recent top-line performance shows sustained double-digit growth across quarterly, annual, and trailing twelve-month measures, supported by employee productivity and a market valuation that prices the company at a premium to sales.

• Q3 2025 revenue: 985.93 million CNY (+16.83% YoY)
• 2024 annual revenue: 2.89 billion CNY (+17.74% YoY vs. 2023)
• TTM revenue: 3.26 billion CNY (+18.40% YoY)
• Revenue per employee: 1.66 million CNY (1,961 employees)
• Price-to-Sales (P/S) ratio: 6.10
• Market capitalization: ~19.90 billion CNY

• Growth drivers implied by the numbers: strong product demand and scalable revenue vs. headcount (1.66M CNY per employee).
• Valuation note: P/S of 6.10 suggests investors are pricing future revenue expansion into market cap (~19.90B CNY).
• Short-term momentum: Q3 2025 growth (16.83% YoY) aligns with TTM strength (18.40% YoY), indicating consistency across recent quarters.

For context on corporate direction that may impact future revenue trajectories, see: Mission Statement, Vision, & Core Values (2026) of Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Profitability Metrics

• Net profit (1H 2025): 140 million CNY - down 37.53% year-over-year.
• Net profit margin (Q3 2025): 17.96% - a 21.19% decline YoY.
• TTM net income: 303.28 million CNY; Diluted EPS (TTM): 0.72 CNY.
• Operating margin (Q3 2025): 22.85%.
• Return on Assets (ROA): 5.27%.
• Return on Equity (ROE): 4.89%.
• Earnings yield (Joel Greenblatt, Q3 2025): 1.41%.

• Short-term investor considerations: margin compression and YoY profit decline.
• Operational strength: above-20% operating margin points to controlled operating costs or favorable product mix.
• Valuation signal: low earnings yield implies investors are pricing in growth or low risk - verify against peers.
• Per-share metrics: diluted EPS 0.72 CNY (TTM) should be assessed vs. historical EPS and forward guidance.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) Debt vs. Equity Structure

• Total assets: 9.70 billion CNY (H1 2025)
• Total liabilities: 3.78 billion CNY (H1 2025)
• Reported debt-to-equity ratio: 0.42
• Current ratio: 0.77
• Quick ratio: 0.44
• Interest coverage ratio: 7.31
• Cash and cash equivalents: 750 million CNY (end 2023) → 470 million CNY (end 2024)

• Balance-sheet strength: with assets of 9.70 billion CNY against liabilities of 3.78 billion CNY, the company retains material net equity on paper, though reported leverage metrics put debt at a moderate level relative to equity (reported debt-to-equity: 0.42).
• Liquidity signals: current ratio of 0.77 and quick ratio of 0.44 point to potential short-term liquidity constraints - working capital may be tight and the company could face pressure meeting near-term obligations without drawing on credit or operating cash flow.
• Interest serviceability: an interest coverage ratio of 7.31 indicates earnings are, at present, sufficient to cover interest expense comfortably, providing a cushion even if liquidity is stretched.
• Cash trend risk: cash and cash equivalents fell from 750 million CNY at end-2023 to 470 million CNY at end-2024, a decline that amplifies short-term liquidity considerations.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) Liquidity and Solvency

• Cash and cash equivalents: 491.93 million CNY as of September 2025 (down 39.74% YoY).
• Current liabilities due within one year: increased from 670.00 million CNY at end-2024 to 730.00 million CNY in H1 2025.
• Operating cash flow (Q3 2025): 223.45 million CNY, a decrease of 27.84% vs. Q3 2024.
• Free cash flow (Q3 2025): -263.26 million CNY (negative FCF, reflecting cash outflows from operations/capex).
• Net change in cash (Q3 2025): -112.86 million CNY, a 186.52% YoY decrease.

• Liquidity pressure: cash reserves have contracted sharply while near-term obligations have risen, compressing the company's margin for error on working capital and unexpected cash demands.
• Operational cash generation weakening: the decline in operating cash flow and negative free cash flow in Q3 2025 indicate cash consumed by operations and investment, raising dependence on external financing or asset dispositions to cover deficits.
• Solvency considerations: the increase in current liabilities relative to cash balances elevates rollover and refinancing risk; covenant breaches or higher borrowing costs could materialize if trends persist.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Valuation Analysis

• Trailing twelve months (TTM) P/E: 59.77
• Forward P/E: 34.51
• Price-to-Book (P/B): 4.38
• Enterprise Value-to-Revenue (EV/R): 8.50
• EV/EBITDA: 27.50 (one reported figure)
• Enterprise value-to-EBITDA (alternate reported): 22.84
• EV/Free Cash Flow (EV/FCF): 460.22
• Market Capitalization: ≈ 19.90 billion CNY

• High P/E and P/B ratios imply significant growth expectations; any earnings disappointments could cause rapid revaluation.
• Elevated EV/EBITDA and EV/R point to a premium for revenue and operating profit - benchmarking vs. peers is essential.
• Very high EV/FCF highlights weak free cash conversion relative to enterprise value; monitor cash flow trends and capex requirements.
• The gap between TTM and forward P/E (59.77 → 34.51) indicates expected earnings growth or one-off TTM impacts-verify drivers.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) - Risk Factors

• Short-term liability pressure: current liabilities due within one year rose from 670 million CNY (end of 2024) to 730 million CNY (H1 2025), tightening near-term liquidity.
• Declining cash reserves: cash and cash equivalents fell from 750 million CNY (end of 2023) to 470 million CNY (end of 2024), reducing the company's buffer for operational needs.
• Negative operating cash flow: free cash flow for Q3 2025 was -263.26 million CNY, signaling cash burn from operations.
• Profitability erosion: Q3 2025 net profit margin was 17.96%, a decline of 21.19% year-over-year, indicating margin pressure.
• Market volatility: the stock experienced an 11.32% drop on October 15, 2025, reflecting investor sensitivity to news or results.
• Leverage profile: debt-to-equity ratio is 0.42, a moderate leverage level that still exposes the company to refinancing and interest-rate risks.

• Liquidity risks: rising short-term payables + shrinking cash balances increase refinancing and working-capital risk.
• Operational cash risk: persistent negative free cash flow could necessitate asset sales, equity issuance, or additional borrowing.
• Profitability and margin risk: a 21.19% YoY drop in net margin for Q3 2025 may reflect pricing, cost, or product-mix challenges.
• Market and sentiment risk: significant share-price declines (e.g., -11.32% on 15 Oct 2025) can raise cost of capital and investor scrutiny.
• Leverage and interest-rate risk: debt-to-equity of 0.42 is moderate but makes the company sensitive to rate changes and refinancing conditions.

Betta Pharmaceuticals Co., Ltd. (300558.SZ) Growth Opportunities

• Late-stage pipeline: imminent launches include a third‑generation EGFR‑TKI and a long‑acting ophthalmic formulation, both reporting promising clinical results (improved efficacy/safety endpoints vs. comparators in recent Phase II/III readouts).
• Early-stage engine: multiple new molecular entities (NMEs) currently in Phase I, broadening therapeutic coverage and de‑risking long‑term revenue streams.
• Analyst expectations: consensus forecasts earnings CAGR of 42.2% and revenue CAGR of 19.2% over the next three years, implying rapid margin expansion as new assets commercialize.
• Valuation trajectory: P/E expected to compress from 52x in 2024 to 22x by 2027; P/B projected to decline from 3.7x to 2.8x over the same period, reflecting anticipated earnings growth and improving market perception.

• Quantifying the growth: a 19.2% revenue CAGR implies ~69.6% cumulative revenue expansion over 3 years (multiplier ≈ 1.696). A 42.2% earnings CAGR implies ~187.5% cumulative earnings growth (multiplier ≈ 2.875) - underpinning the projected P/E compression.
• Profitability and capital efficiency: ROE rising to 11.9% by 2027 signals improved return dynamics as higher-margin innovative products scale and R&D investment shifts toward later-stage commercialization.
• Investment implications: the combination of rapid earnings growth and lower forward P/E/P/B suggests upside to equity returns if clinical readouts and launches proceed as expected; conversely, execution risk (regulatory delays, pricing pressure) remains a key sensitivity.